8-K: ImmunityBio Reports Strong Q1 2025 Results: Revenue Doubles, ANKTIVA Sales Surge

ImmunityBio announces a 129% increase in net product revenue and a 150% growth in ANKTIVA unit sales volume for Q1 2025, driven by the permanent J-code and expanded access program.

Summary

• ImmunityBio reported its Q1 2025 financial results, highlighting significant growth in revenue and sales volume.
• Net product revenue reached approximately $16.5 million, a 129% increase compared to $7.2 million in Q4 2024.
• ANKTIVA unit sales volume grew by 150% in Q1 2025 compared to the previous quarter, with March sales up 69% from February.
• Nearly 200 urology practices are registering for the recombinant BCG (rBCG) Expanded Access Program (EAP).
• The company completed a $75 million equity financing in April 2025 to support ongoing operations.
• Research and development expenses decreased by $5.1 million to $48.2 million.
• Selling, general, and administrative expenses decreased by $9.2 million to $32.7 million.
• Net loss attributable to ImmunityBio common stockholders was $129.6 million, an improvement from $134.1 million in the same period last year.
• As of March 31, 2025, the company had $136.4 million in cash and marketable securities on a pro forma basis.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and sales momentum, but the continued net losses and reliance on financing temper the overall sentiment.

Positives

• Significant revenue growth driven by ANKTIVA sales.
• Strong unit sales volume increase for ANKTIVA.
• Successful launch of the rBCG Expanded Access Program.
• Decrease in research and development expenses.
• Decrease in selling, general, and administrative expenses.
• Reduced net loss compared to the previous year.
• Successful equity financing to bolster cash position.

Negatives

• The company still reported a net loss of $129.6 million for the quarter.
• The company has a significant amount of related-party debt at $485.7 million.
• The company has a significant revenue interest liability of $296.2 million.

Risks

• The company's future performance depends on the continued adoption of ANKTIVA and the success of its pipeline.
• Regulatory risks associated with drug development and approval remain a concern.
• The company's ability to manage its expenses and achieve profitability is crucial.
• The company's ability to obtain additional financing to fund its operations is a risk factor.

Future Outlook

The company anticipates continued growth in revenue and sales volume, driven by the adoption of ANKTIVA and the expansion of the rBCG EAP. They are also progressing with their pipeline development, including a second-line lung cancer study and an EAP protocol for ANKTIVA for the treatment of lymphopenia.

Management Comments

• Richard Adcock, President and CEO of ImmunityBio, stated that they are seeing steady revenue growth as urologists increase their use of ANKTIVA, particularly since addressing the BCG shortage with the launch of their rBCG EAP.
• Dr. Patrick Soon-Shiong, Founder, Executive Chairman, Global Chief Scientific & Medical Officer of ImmunityBio, noted the real-world benefits of their unique approach to immunotherapy and the progress in developing their pipeline.

Industry Context

ImmunityBio operates in the competitive immunotherapy market, focusing on cancer and infectious diseases. The company's success depends on its ability to differentiate its products and secure market share. The J-code approval and rBCG EAP are significant steps in expanding access to ANKTIVA and addressing unmet needs in the bladder cancer treatment landscape.

Comparison to Industry Standards

• Comparing ImmunityBio's revenue growth to other immunotherapy companies like Bristol Myers Squibb or Merck, which have established blockbuster drugs, shows that ImmunityBio is still in an early growth phase.
• The 150% unit sales growth of ANKTIVA is a positive sign, but it needs to be sustained to compete effectively with established therapies like Keytruda or Opdivo.
• The rBCG EAP addresses a critical shortage, giving ImmunityBio a competitive advantage over companies relying on traditional BCG supply chains.
• The company's focus on IL-15-based therapies differentiates it from companies primarily focused on checkpoint inhibitors or CAR-T cell therapies.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and sales growth.
• Patients will have greater access to ANKTIVA and rBCG treatments.
• Employees will benefit from the company's growth and expansion.
• Urologists will have a new treatment option for NMIBC patients.

Next Steps

• Continue to expand the rBCG Expanded Access Program.
• Advance the second-line lung cancer study.
• Pursue the EAP protocol for ANKTIVA for the treatment of lymphopenia.
• Potentially submit a BLA for lymphopenia treatment.

Key Dates

Keywords

ImmunityBio, ANKTIVA, rBCG, J-code, Revenue, Immunotherapy, NMIBC, Financial Results, Clinical Trial, EAP